Overall, researchers have shown that chemotherapy, certain targeted therapies, radiotherapy, vaccination, and oncolytic viruses upregulate PD-L1 in certain cancers, which makes them ideal candidates to be tested for combination therapy with anti-PD-1/PD-L1 ICBs. This evidence concerns the gene CD274 and cancer.